Charles Schwab Investment Management Inc. Purchases 5,413 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)

Charles Schwab Investment Management Inc. lifted its holdings in Candel Therapeutics, Inc. (NASDAQ:CADL) by 11.6% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 52,190 shares of the company’s stock after purchasing an additional 5,413 shares during the period. Charles Schwab Investment Management Inc. owned about 0.16% of Candel Therapeutics worth $453,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC purchased a new stake in Candel Therapeutics during the third quarter valued at approximately $46,000. MetLife Investment Management LLC bought a new stake in shares of Candel Therapeutics during the 3rd quarter valued at $87,000. Atom Investors LP purchased a new stake in shares of Candel Therapeutics in the 3rd quarter worth $103,000. Rhumbline Advisers increased its stake in shares of Candel Therapeutics by 17.0% in the 4th quarter. Rhumbline Advisers now owns 26,272 shares of the company’s stock worth $228,000 after purchasing an additional 3,817 shares in the last quarter. Finally, Barclays PLC raised its holdings in Candel Therapeutics by 327.1% in the 3rd quarter. Barclays PLC now owns 28,688 shares of the company’s stock worth $199,000 after purchasing an additional 21,971 shares during the period. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Bank of America began coverage on Candel Therapeutics in a research report on Friday, February 7th. They issued a “buy” rating and a $15.00 price target for the company. Citigroup started coverage on Candel Therapeutics in a research note on Thursday, February 20th. They set a “buy” rating and a $25.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $19.00 target price on shares of Candel Therapeutics in a research note on Friday, March 14th. Finally, Canaccord Genuity Group lifted their price target on shares of Candel Therapeutics from $20.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, February 26th.

Candel Therapeutics Stock Down 5.0 %

Shares of Candel Therapeutics stock opened at $5.65 on Tuesday. The company has a market capitalization of $266.88 million, a price-to-earnings ratio of -3.27 and a beta of -1.29. The stock’s 50-day simple moving average is $8.18 and its 200-day simple moving average is $7.05. Candel Therapeutics, Inc. has a 52 week low of $1.56 and a 52 week high of $14.60.

Candel Therapeutics (NASDAQ:CADL) last issued its earnings results on Thursday, March 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.17). On average, equities analysts expect that Candel Therapeutics, Inc. will post -1.47 earnings per share for the current year.

Insider Activity

In other Candel Therapeutics news, insider Charles Schoch sold 5,000 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $8.83, for a total transaction of $44,150.00. Following the completion of the transaction, the insider now owns 38,038 shares of the company’s stock, valued at $335,875.54. This represents a 11.62 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CTO Seshu Tyagarajan sold 31,278 shares of the firm’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $8.82, for a total value of $275,871.96. Following the transaction, the chief technology officer now owns 85,512 shares of the company’s stock, valued at approximately $754,215.84. The trade was a 26.78 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 77,807 shares of company stock worth $633,534 over the last quarter. Insiders own 41.60% of the company’s stock.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.